A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis

Newly diagnosed AL amyloidosis patients were evaluated to develop a model for early assessment of treatment benefit at 6 months, integrating both hematologic (HR) and organ response (OR) assessment (testing cohort, Mayo: n = 473; validation cohort, Pavia: n = 575). Multiple OR were assessed as follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidana, Surbhi, Milani, Paolo, Binder, Moritz, Basset, Marco, Tandon, Nidhi, Foli, Andrea, Dispenzieri, Angela, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Lacy, Martha Q., Kapoor, Prashant, Leung, Nelson, Rajkumar, S. Vincent, Merlini, Giampaolo, Palladini, Giovanni, Kumar, Shaji K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156647/
https://www.ncbi.nlm.nih.gov/pubmed/32286270
http://dx.doi.org/10.1038/s41408-020-0306-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156647/
https://www.ncbi.nlm.nih.gov/pubmed/32286270
http://dx.doi.org/10.1038/s41408-020-0306-5

Ejemplares similares